References
- Deyo RA, Walsh NE, Schoenfeld LS, Ramamurthy S. Can trials of physical treatments be blinded? The example of transcutaneous electrical nerve stimulation for chronic pain. Am J Phys Med Rehabil. 1990;69:6–10.
- Kaptchuk TJ, Goldman P, Stone DA, Stason WB. Do medical devices have enhanced placebo effects? J Clin Epidemiol. 2000;53:786–792.
- Kaptchuk TJ, Stason WB, Davis RB, et al. Sham device v inert pill: randomised controlled trial of two placebo treatments. BMJ. 2006;332:391–397.
- Burbank F, Buchfuhrer MJ, Kopjar B. Sleep improvement for restless legs syndrome patients. Part I: Pooled analysis of two prospective, double-blind, sham-controlled, multi-center, randomized clinical studies of the effects of vibrating pads on RSL symptoms. Journal of Parkinsonism and Restless Legs Syndrome. 2013;3:1–10.
- Burbank F, Buchfuhrer MJ, Kopjar B. Improving sleep for patients with restless legs syndrome. Part II. Meta-analysis of vibration therapy and drugs approved by the FDA for treatment of restless legs syndrome. J Parkinsonism Restless Legs Syndrome. 2013;3:11–22.
- Allen RP, Kosinski M, Hill-Zabala CE, Calloway MO. Psychometric evaluation and tests of validity of the Medical Outcomes Study 12-item Sleep Scale (MOS sleep). Sleep Med. 2009;10:531–539.
- Hays RD, Stewart AL. Sleep measures. In Stewart AL, Ware JE, Jr, editors. Measuring Functioning and Well-Being: The Medical Outcomes Study approach. Durham: Duke University Press; 1998:235–259.
- Hays RD, Martin SA, Sesti AM, Spritzer KL. Psychometric properties of the Medical Outcomes Study Sleep measure. Sleep Med. 2005;6:41–44.
- Burbank F. Sleep improvement for restless legs syndrome patients. Part III: Effects of treatment assignment belief on sleep improvement in restless legs syndrome patients. A mediation analysis. J Parkinsonism Restless Legs Syndrome. 2013;3:23–29.
- Ernst E. Belief can move mountains. Eval Health Prof. 2005;28:7–8.
- Fulda S, Wetter TC. Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies. Brain. 2008;131:902–917.
- Morris SB, DeShon RP. Combining effect sizes in meta-analysis with repeated measures and independent groups designs. Psychol Methods. 2002;7:105–125.
- Hedges LV. Estimation of effect size from a series of independent experiments. Psychol Bull. 1982;92:490–499.
- Borenstein M, Hedges LV, Higgins J, Rothstein H. Introduction to Meta-Analysis. West Sussex, UK: John Wiley & Sons Ltd; 2009.
- Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.
- Hedges LV. Distribution theory for Glass’s estimator of effect size and related estimators. J Educ Stat. 1981;6:107–128.
- Oertel WH, Stiasny-Kolster K, Bergtholdt B, et al. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov Disord. 2007;22:213–219.
- Allen R, Becker PM, Bogan R, et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep. 2004;27:907–914.
- GlaxoSmithKline. Results summary for RRL100013. Available from: http://www.gsk-clinicalstudyregister.com/quick-search-list.jsp?item=100013&type=GSK+Study+ID&studyId=100013. Accessed November 8, 2013.
- GlaxoSmithKline. Results summary for ROP101892. Available from: http://www.gsk-clinicalstudyregister.com/quick-search-list.jsp?item=101892&type=GSK+Study+ID&studyId=101892. Accessed November 8, 2013.
- Bogan RK, Fry JM, Schmidt MH, Carson SW, Ritchie SY. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc. 2006;81:17–27.
- Stiasny-Kolster K, Benes H, Peglau I, et al. Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology. 2004;63:2272–2279.
- Oertel WH, Benes H, Bodenschatz R, et al. Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR). Neurology. 2006;67:1040–1046.
- Boghen D, Lamothe L, Elie R, Godbout R, Montplaisir J. The treatment of the restless legs syndrome with clonazepam: a prospective controlled study. Can J Neurol Sci. 1986;13:245–247.
- Wetter TC, Stiasny K, Winkelmann J, et al. A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology. 1999;52:944–950.
- Benes H, Kurella B, Kummer J, Kazenwadel J, Selzer R, Kohnen R. Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial. Sleep. 1999;22:1073–1081.
- GlaxoSmithKline. Results summary for 101468/190. Available from: http://www.gsk-clinicalstudyregister.com/quick-search-list.jsp?item=101468%2f190&type=GSK+Study+ID&studyId=101468%2f190. November 8, 2013.
- GlaxoSmithKline. Results summary for 101468/194. Available from: http://www.gsk-clinicalstudyregister.com/quick-search-list.jsp?item=101468%2f194&type=GSK+Study+ID&studyId=101468%2f194. Accessed November 8, 2013.
- Sensory Medical. NCT00s877916 and NCT01145651 trial summaries. 2012. Available from: http://www.sensorymedical.com. Accessed March 29, 2012.
- Kales A, Manfredi RL, Vgontzas AN, Baldassano CF, Kostakos K, Kales JD. Clonazepam: sleep laboratory study of efficacy and withdrawal. J Clin Psychopharmacol. 1991;11:189–193.
- Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson’s disease. Neurology. 2001;57:1392–1396.